Searchable abstracts of presentations at key conferences in endocrinology

ea0029p579 | Diabetes | ICEECE2012

Relationship vitamin D levels and glycemic control in type 2 diabetic patient

Oz Gul O , Gul B , Cander S , Eroglu A , Keni N , Ersoy C , Imamoglu S

Objective: Vitamin D deficiency has been shown to alter insulin synthesis and secretion in both humans and animal models. However, less is known on the association between vitamin D and type 2 diabetes mellitus. In the current study we aimed to analyze the relationship between vitamin D levels with glycemic control in type 2 diabetic patients.Material and methods: Three hundred and twenty diabetic patients who are follow up at least 6 months for diabetes...

ea0029p670 | Diabetes | ICEECE2012

The Relationship between Cognitive Function and Microalbuminuria in Elderly Type 2 Diabetic Patients

Oz Gul O. , Gul C. , Hartavi M. , Bayindir A. , Cander S. , Ersoy C. , Imamoglu S.

Objective: The prevalence and incidence of diabetes mellitus (DM) are increasing at all ages, including older populations. Several studies have shown that elderly diabetics have impaired cognitive function compared to age-matched non-diabetics, as well as a higher risk of dementia. In the current study we aimed to analyze relationship between microalbuminuria and cognitive dysfunction in elderly patients with type 2 diabetes.Material and Methods: One hun...

ea0029p1479 | Pituitary Clinical | ICEECE2012

Treatment outcomes in prolactinomas with and without cavernous sinus invasion

Oz Gul O , Cander S , Erturk E , Unal O , Ersoy C , Tuncel E , Imamoglu S

In prolactinomas, today first choice of treatment is medical treatment with dopamine agonists. Cavernous sinus invasion is not uncommon in prolactinomas and stands out as a blocking factor for surgical removal of the tumor fully. In our study, the presence of cavernous sinus invasion was to investigate the effect on the results of surgical and medical treatment in prolactinomas.Eighty-seven patients followed up with a diagnosis of prolactinoma were inclu...

ea0029p1485 | Pituitary Clinical | ICEECE2012

Prolactin levels are correlated with tumor size and invasiveness in prolactinomas

Cander S , Erturk E , Oz Gul O , Unal O , Ersoy C , Tuncel E , Imamoglu S

Prolactinomas are more common tumors by 60% among the hypophysis adenomas. These are often benign, but may present differences in terms of tumor size and treatment responses. Aim of this study was investigate the relationship of serum prolactin levels with tumor size and invasiveness in the prolactinomas.113 patients with the diagnosis of prolactinoma were included to study. Pretreatment plasma levels of prolactin in the time of diagnosis and sella MR im...

ea0029p1426 | Pituitary Clinical | ICEECE2012

Comprasion of cycline D1 gene (Ccnd1) polymorphism in invasive and non-invasive prolactinomas

Cander S. , Erturk E. , Karkucak M. , Oz Gul O. , Yakut T. , Unal O. , Ersoy C. , Tuncel E. , Imamoglu S.

Cycline D1 gene that plays a crucial role in a cell cycle, have been shown to be expressed more in nonfunctioning pituitary adenomas and functioning invasive pituitary adenomas compared to normal hypophisis tissue and noninvasive pituitary adenomas. A/G polymorphism in CyD1 gene exon 4/intron 4 regions have been demonstrated to affect clinical outcomes and survey in some tumors. Objective of this study was to investigate the effect of polymorphism of cycline D1 gene on the tum...

ea0029p1459 | Pituitary Clinical | ICEECE2012

The effect of Ki67 index on tumor behavior in proloctanimas

Cander S. , Erturk E. , Oz Gul O. , Saraydaroglu O. , Unal O. , Ersoy C. , Tuncel E. , Imamoglu S.

Majority of prolactinomas consists of the small microadenomas that can be treated with dopamine agonists, but they can present different biological behavior features and not infrequently seen as macroadenomas or in giant adenoma size. There are different results on finding of studies which investigate the relationship between high levels of cell proliferation indicators with tumor behavior in pituitary adenomas. In this study, Ki 67 index to investigate the relationship betwee...

ea0026p674 | Diabetes therapy | ECE2011

Effect of sitagliptin monotherapy on serum total ghrelin levels in type 2 diabetic patients

Oz Gul O , Kiyici S , Ersoy C , Cander S , Unal O K , Erturk E , Tuncel E , Imamoglu S

Background: Sitagliptin, unlike the some major antihyperglycaemic drugs, is not associated with weight gain and has neutral effects on body weight. It is unclear whether sitagliptin treatment alters serum ghrelin levels in people with type 2 diabetes. The aim of the present study was to assess the effect of sitagliptin on serum ghrelin levels in patients with type 2 diabetes mellitus.Methods: Forty-four type 2 diabetic subjects were randomly assigned to ...